Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 940-946

  Shirakawa, Mitsuhiro ^a   Fujiwara, Yoshiyuki ^a   Sugita, Yurika ^a   Moon, Jeong Ho ^a   Takiguchi, Shuji ^a   Nakajima, Kiyokazu ^a   Miyata, Hiroshi ^a   Yamasaki, Makoto ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophageal carcinoma; HIF 1; p53; Stanniocalcin 1

Indexed keywords

GLYCOPROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN P53; STANNIOCALCIN 1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL CULTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE MARKER; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84856566829     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1607     Document Type: Article

References (32)

1. Sugimachi K, Matsuura H, Kai H, et al: Prognostic factors of esophageal carcinoma: univariate and multivariate analyses. J Surg Oncol 31: 108-112, 1986. (Pubitemid 16165863)
2. Natsugoe S, Matsumoto M, Okumura H, et al: Prognostic factors in patients with submucosal esophageal cancer. J Gastrointest Surg 8: 631-635, 2004. (Pubitemid 38881422)
3. Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 15: 4592-4596, 2003. (Pubitemid 46594032)
4. Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26: 1086-1092, 2008.
5. Fontaine M: Stannius' corpuscles and ionic (Ca, K, Na) of the interior environment of the eel (Anguilla Anguilla L). C R Hebd Seances Acad Sci 259: 875-878, 1964.
6. Chang ACM, Janosi J, Hulsbeek M, et al: A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol 112: 241-247, 1995.
7. Chang AC and Reddel RR: Identification of a second Stanniocalcin cDNA in mouse and human: stanniocalcin 2. Mol Cell Endocrinol 141: 95-99, 1998. (Pubitemid 28393383)
8. Fujiwara Y, Sugita Y, Nakamori S, et al: Assessment of Stanniocalcin- 1 mRNA as a molecular marker for micrometastases of various human cancers. Int J Oncol 16: 799-804, 2000.
9. Nakagawa T, Martinez SR, Goto Y, et al: Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res 13: 4105-4110, 2007. (Pubitemid 47105972)
10. Joensuu K, Heikkilä P and Andersson LC: Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett 265: 76-83, 2008.
11. Law AY, Ching LY, Lai KP, et al: Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. Mol Cell Endocrinol 314: 118-127, 2010.
12. Matsuyama J, Doki Y, Yasuda T, et al: The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 141: 570-580, 2007. (Pubitemid 46616931)
13. Yano M, Takachi K, Doki Y, et al: Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus 19: 158-163, 2006.
14. Yamasaki M, Miyata H, Fujiwara Y, et al: p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol 17: 634-642, 2010.
15. Makino T, Yamasaki M, Miyata H, et al: p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol 17: 804-811, 2010.
16. Wascher RA, Huynh KT, Giuliano AE, et al: Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. Clin Cancer Res 9: 1427-1435, 2003. (Pubitemid 36418397)
17. Paulitschke V, Kunstfeld R, Mohr T, et al: Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res 8: 2501-2510, 2009.
18. Chang AC, Jellinek DA and Reddel RR: Mammalian stanniocalcins and cancer. Endocr Relat Cancer 10: 359-373, 2003. (Pubitemid 37267555)
19. McCudden CR, James KA, Hasilo C and Wagner GF: Characterization of mammalian stanniocalcin receptors. Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism. J Biol Chem 277: 45249-45258, 2002. (Pubitemid 36159130)
20. Maxwell PH, Dachs GU, Gleadle JM, et al: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94: 8104-8109, 1997. (Pubitemid 27343784)
21. Wang GL, Jiang BH and Semenza GL: Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1. Biochem Biophys Res Commun 212: 550-556, 1995.
22. Yeung HY, Lai KP, Chan HY, et al: Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology 146: 4951-4960, 2005. (Pubitemid 41446634)
23. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992, 1998.
24. Lai KP, Law AY, Yeung HY, et al: Induction of stanniocalcin-1 expression in apoptotic human nasopharyngeal cancer cells by p53. Biochem Biophys Res Commun 356: 968-975, 2007. (Pubitemid 46529385)
25. Brown JM and Wilson WR: Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447, 2004. (Pubitemid 38745529)
26. Vaupel P, Thews O and Hoeckel M: Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18: 243-259, 2001. (Pubitemid 34044509)
27. Cohen P and Frame S: The renaissance of GSK3 (Review). Nat Rev Mol Cell Biol 2: 769-776, 2001. (Pubitemid 33679839)
28. Thompson JE and Thompson CB: Putting the rap on Akt. J Clin Oncol 22: 4217-4226, 2004. (Pubitemid 41185193)
29. Comerford KM, Wallace TJ, Karhausen J, et al: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394, 2002. (Pubitemid 34651384)
30. Sullivan R, Paré GC, Frederickson LJ, et al: Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 7: 1961-1973, 2008.
31. Kita Y, Mimori K, Iwatsuki M, et al: STC2: A predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma. Ann Surg Oncol 18: 261-272, 2011.
32. Law AY and Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res 316: 466-476, 2010.